Tonix reports preliminary Q2 net operating loss of $26.3M, cash $125.3M, runway to Q3 2026

Tonix Pharmaceuticals Holding Corp.

2025-Q2 EPS reported -$6.80 vs consensus -$3.28 ▼ miss (-107.4%)

Net operating loss of $26.3M in Q2 2025, improved from $78.8M in Q2 2024.
Cash and equivalents $125.3M at June 30; additional $50.6M raised in Q3 2025 equity offerings.
Net cash used in ops $16.3M ($9.9M in Q2 2024); capex $1.1M (nil prior year).
Revenue from marketed products $2.0M, down from $2.2M YoY.
Company expects runway into Q3 2026; shares outstanding 8.7M as of July 25.

item 2.02item 8.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.